Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations
- 1 April 2003
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (4) , 207-218
- https://doi.org/10.1097/00008571-200304000-00005
Abstract
Several mutations are known or suspected to affect mRNA splicing of CYP2C19, CYP2D6 and CYP3A5 genes; however, little experimental evidence exists to support these conclusions. The present study applies mathematical models that measure changes in information content of splice sites in these genes to demonstrate the relationship between the predicted phenotypes of these variants to the corresponding genotypes. Based on information analysis, the CYP2C19*2 variant activates a new cryptic site 40 nucleotides downstream of the natural splice site. CYP2C19*7 abolishes splicing at the exon 5 donor site. The CYP2D6*4 allele similarly inactivates splicing at the acceptor site of exon 4 and activates a new cryptic site one nucleotide downstream of the natural acceptor. CYP2D6*11 inactivates the acceptor site of exon 2. The CYP3A5*3 allele activates a new cryptic site 236 nucleotides upstream of the exon 4 natural acceptor site. CYP3A5*5 inactivates the exon 5 donor site and CYP3A5*6 strengthens a site upstream of the natural donor site, resulting in skipping of exon 7. Other previously described missense and nonsense mutations at terminal codons of exons in these genes affected splicing. CYP2D6*8 and CYP2D6*14 both decrease the strength of the exon 3 donor site, producing transcripts lacking this exon. The results of information analysis are consistent with the poor metabolizer phenotypes observed in patients with these mutations, and illustrate the potential value of these mathematical models to quantitatively evaluate the functional consequences of new mutations suspected of altering mRNA splicing.Keywords
This publication has 33 references indexed in Scilit:
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNature Genetics, 2001
- Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataPharmacogenetics and Genomics, 1999
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationPharmacogenetics, 1998
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- Biochemistry and molecular biology of the human CYP2C subfamilyPharmacogenetics, 1994
- Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoinClinical Pharmacology & Therapeutics, 1992
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977